Importance of circulating antibodies in protection against meningococcal disease
Neisseria meningitidis infection results in life-threatening illnesses, including bacteremia, sepsis and meningitis. Early diagnosis and treatment are a challenge due to rapid disease progression, resulting in high mortality and morbidity in survivors. Disease can occur in healthy individuals, howev...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2012-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.4161/hv.20473 |
| _version_ | 1797632977710088192 |
|---|---|
| author | Kim S. Erlich Blaise L. Congeni |
| author_facet | Kim S. Erlich Blaise L. Congeni |
| author_sort | Kim S. Erlich |
| collection | DOAJ |
| description | Neisseria meningitidis infection results in life-threatening illnesses, including bacteremia, sepsis and meningitis. Early diagnosis and treatment are a challenge due to rapid disease progression, resulting in high mortality and morbidity in survivors. Disease can occur in healthy individuals, however, risk of infection is higher in patients with certain risk factors. N meningitidis carriage and case-fatality rates are high in adolescents and young adults. The absolute incidence of meningococcal disease has decreased partially due to increasing meningococcal vaccination rates. Maintaining protective levels of circulating antibodies by vaccination is necessary for clinical protection against disease. The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices guidelines recommend vaccination for all individuals aged 11 through 12 years, followed by a booster dose at age 16 years for maintenance of protective antibody levels throughout the high-risk years. Despite these guidelines, many adolescents remain unvaccinated and susceptible to infection and disease. |
| first_indexed | 2024-03-11T11:44:22Z |
| format | Article |
| id | doaj.art-2b35bbeec47c438f8a08605dfacc1421 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T11:44:22Z |
| publishDate | 2012-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-2b35bbeec47c438f8a08605dfacc14212023-11-09T15:17:18ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2012-08-01881029103510.4161/hv.20473Importance of circulating antibodies in protection against meningococcal diseaseKim S. Erlich0Blaise L. Congeni1Associate Clinical Professor, University of California, San Francisco; Daly City, CA USADirector, Pediatric Infectious Disease, Division of Infectious Disease; Akron Children’s Hospital; Akron, OH USANeisseria meningitidis infection results in life-threatening illnesses, including bacteremia, sepsis and meningitis. Early diagnosis and treatment are a challenge due to rapid disease progression, resulting in high mortality and morbidity in survivors. Disease can occur in healthy individuals, however, risk of infection is higher in patients with certain risk factors. N meningitidis carriage and case-fatality rates are high in adolescents and young adults. The absolute incidence of meningococcal disease has decreased partially due to increasing meningococcal vaccination rates. Maintaining protective levels of circulating antibodies by vaccination is necessary for clinical protection against disease. The Centers for Disease Control and Prevention Advisory Committee on Immunization Practices guidelines recommend vaccination for all individuals aged 11 through 12 years, followed by a booster dose at age 16 years for maintenance of protective antibody levels throughout the high-risk years. Despite these guidelines, many adolescents remain unvaccinated and susceptible to infection and disease.https://www.tandfonline.com/doi/10.4161/hv.20473meningococcal diseaseNeisseria meningitidiscirculating antibodiesprotective antibodiesmeningococcal conjugate vaccinesadolescent health |
| spellingShingle | Kim S. Erlich Blaise L. Congeni Importance of circulating antibodies in protection against meningococcal disease Human Vaccines & Immunotherapeutics meningococcal disease Neisseria meningitidis circulating antibodies protective antibodies meningococcal conjugate vaccines adolescent health |
| title | Importance of circulating antibodies in protection against meningococcal disease |
| title_full | Importance of circulating antibodies in protection against meningococcal disease |
| title_fullStr | Importance of circulating antibodies in protection against meningococcal disease |
| title_full_unstemmed | Importance of circulating antibodies in protection against meningococcal disease |
| title_short | Importance of circulating antibodies in protection against meningococcal disease |
| title_sort | importance of circulating antibodies in protection against meningococcal disease |
| topic | meningococcal disease Neisseria meningitidis circulating antibodies protective antibodies meningococcal conjugate vaccines adolescent health |
| url | https://www.tandfonline.com/doi/10.4161/hv.20473 |
| work_keys_str_mv | AT kimserlich importanceofcirculatingantibodiesinprotectionagainstmeningococcaldisease AT blaiselcongeni importanceofcirculatingantibodiesinprotectionagainstmeningococcaldisease |